Eribulin in advanced liposarcoma and leiomyosarcoma.

Elisabetta Setola, Jonathan Noujaim, Charlotte Benson, Sant Chawla, Emanuela Palmerini, Robin L. Jones

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The heterogeneity of soft tissue sarcomas (STS) presents a formidable management challenge. Consequently, one of the main research goals is to define specific tailored therapy for each histological subtype and to develop a more personalised approach to treatment. The standard first line chemotherapy for advanced STS is doxorubicin, with or without ifosfamide, however, a number of different drugs are emerging as active therapies beyond first-line. Areas covered: Eribulin has recently been approved for advanced liposarcoma, after an anthracycline-containing regimen, demonstrating an overall survival (OS) advantage in liposarcoma and leiomyosarcoma in a randomised Phase III clinical trial. In this manuscript, an overview of the efficacy and safety of eribulin in STS is presented, highlighting different clinical outcomes between histological subtypes and comparing data with other effective drugs used in the treatment of sarcomas. The potential mechanisms of action of eribulin are also described, including its activity as potent microtubule-destabilizing anticancer agent, which has other antitumor biological effects. Expert commentary: Eribulin is highly effective in some STS populations and also has an acceptable toxicity profile. Further studies are required to better understand the precise mechanism of action of this agent and potential role in combination schedules.
Original languageEnglish
Pages (from-to)717-723
Number of pages7
JournalExpert Review of Anticancer Therapy
Volume17
Issue number8
DOIs
Publication statusPublished - Jun 17 2017

Fingerprint

eribulin
Liposarcoma
Leiomyosarcoma
Sarcoma
Action Potentials
Phase III Clinical Trials
Ifosfamide
Anthracyclines
Therapeutics
Microtubules
Pharmaceutical Preparations
Antineoplastic Agents
Doxorubicin
Appointments and Schedules
Randomized Controlled Trials
Safety
Drug Therapy

Keywords

  • Eribulin
  • eribulin biological effects
  • histology-driven therapy
  • liposarcoma
  • overall survival
  • soft tissue sarcomas

Cite this

Eribulin in advanced liposarcoma and leiomyosarcoma. / Setola, Elisabetta; Noujaim, Jonathan; Benson, Charlotte; Chawla, Sant; Palmerini, Emanuela; Jones, Robin L.

In: Expert Review of Anticancer Therapy, Vol. 17, No. 8, 17.06.2017, p. 717-723.

Research output: Contribution to journalArticle

Setola, Elisabetta ; Noujaim, Jonathan ; Benson, Charlotte ; Chawla, Sant ; Palmerini, Emanuela ; Jones, Robin L. / Eribulin in advanced liposarcoma and leiomyosarcoma. In: Expert Review of Anticancer Therapy. 2017 ; Vol. 17, No. 8. pp. 717-723.
@article{2e0830c00f354aeeb43c48df67db7412,
title = "Eribulin in advanced liposarcoma and leiomyosarcoma.",
abstract = "The heterogeneity of soft tissue sarcomas (STS) presents a formidable management challenge. Consequently, one of the main research goals is to define specific tailored therapy for each histological subtype and to develop a more personalised approach to treatment. The standard first line chemotherapy for advanced STS is doxorubicin, with or without ifosfamide, however, a number of different drugs are emerging as active therapies beyond first-line. Areas covered: Eribulin has recently been approved for advanced liposarcoma, after an anthracycline-containing regimen, demonstrating an overall survival (OS) advantage in liposarcoma and leiomyosarcoma in a randomised Phase III clinical trial. In this manuscript, an overview of the efficacy and safety of eribulin in STS is presented, highlighting different clinical outcomes between histological subtypes and comparing data with other effective drugs used in the treatment of sarcomas. The potential mechanisms of action of eribulin are also described, including its activity as potent microtubule-destabilizing anticancer agent, which has other antitumor biological effects. Expert commentary: Eribulin is highly effective in some STS populations and also has an acceptable toxicity profile. Further studies are required to better understand the precise mechanism of action of this agent and potential role in combination schedules.",
keywords = "Eribulin, eribulin biological effects, histology-driven therapy, liposarcoma, overall survival, soft tissue sarcomas",
author = "Elisabetta Setola and Jonathan Noujaim and Charlotte Benson and Sant Chawla and Emanuela Palmerini and Jones, {Robin L.}",
year = "2017",
month = "6",
day = "17",
doi = "10.1080/14737140.2017.1344098",
language = "English",
volume = "17",
pages = "717--723",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "8",

}

TY - JOUR

T1 - Eribulin in advanced liposarcoma and leiomyosarcoma.

AU - Setola, Elisabetta

AU - Noujaim, Jonathan

AU - Benson, Charlotte

AU - Chawla, Sant

AU - Palmerini, Emanuela

AU - Jones, Robin L.

PY - 2017/6/17

Y1 - 2017/6/17

N2 - The heterogeneity of soft tissue sarcomas (STS) presents a formidable management challenge. Consequently, one of the main research goals is to define specific tailored therapy for each histological subtype and to develop a more personalised approach to treatment. The standard first line chemotherapy for advanced STS is doxorubicin, with or without ifosfamide, however, a number of different drugs are emerging as active therapies beyond first-line. Areas covered: Eribulin has recently been approved for advanced liposarcoma, after an anthracycline-containing regimen, demonstrating an overall survival (OS) advantage in liposarcoma and leiomyosarcoma in a randomised Phase III clinical trial. In this manuscript, an overview of the efficacy and safety of eribulin in STS is presented, highlighting different clinical outcomes between histological subtypes and comparing data with other effective drugs used in the treatment of sarcomas. The potential mechanisms of action of eribulin are also described, including its activity as potent microtubule-destabilizing anticancer agent, which has other antitumor biological effects. Expert commentary: Eribulin is highly effective in some STS populations and also has an acceptable toxicity profile. Further studies are required to better understand the precise mechanism of action of this agent and potential role in combination schedules.

AB - The heterogeneity of soft tissue sarcomas (STS) presents a formidable management challenge. Consequently, one of the main research goals is to define specific tailored therapy for each histological subtype and to develop a more personalised approach to treatment. The standard first line chemotherapy for advanced STS is doxorubicin, with or without ifosfamide, however, a number of different drugs are emerging as active therapies beyond first-line. Areas covered: Eribulin has recently been approved for advanced liposarcoma, after an anthracycline-containing regimen, demonstrating an overall survival (OS) advantage in liposarcoma and leiomyosarcoma in a randomised Phase III clinical trial. In this manuscript, an overview of the efficacy and safety of eribulin in STS is presented, highlighting different clinical outcomes between histological subtypes and comparing data with other effective drugs used in the treatment of sarcomas. The potential mechanisms of action of eribulin are also described, including its activity as potent microtubule-destabilizing anticancer agent, which has other antitumor biological effects. Expert commentary: Eribulin is highly effective in some STS populations and also has an acceptable toxicity profile. Further studies are required to better understand the precise mechanism of action of this agent and potential role in combination schedules.

KW - Eribulin

KW - eribulin biological effects

KW - histology-driven therapy

KW - liposarcoma

KW - overall survival

KW - soft tissue sarcomas

U2 - 10.1080/14737140.2017.1344098

DO - 10.1080/14737140.2017.1344098

M3 - Article

VL - 17

SP - 717

EP - 723

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 8

ER -